





Item 8.01. Other Events.

On December 11, 2017, TG Therapeutics, Inc. (the “Company”) issued a press release announcing clinical and preclinical data presented involving the Company’s lead compounds, TGR-1202 (umbralisib), the Company's once-daily PI3K delta inhibitor, and TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, at the 59th American Society of Hematology (ASH) annual meeting, being held at the Georgia World Congress Center in Atlanta, Georgia. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated December 11, 2017.

-2-



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

Date: December 11, 2017

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer